Bekaplermin
Bekaplermin (Regranex) cikatrizant je koji je dostupa u obliku topikalnog gela. On se koristi za tretiranje dijabetičkih čireva stopala.[1] Bekaplermin se proizvodi primenom rekombinantne DNK tehnologije na kvascu Saccharomyces cerevisiae. Bekaplermin je homodimer čiji polipeptidni lanci su vezani disulfidnim vezama[2][3]
 | |
| Klinički podaci | |
|---|---|
| Prodajno ime | Regranex, Regranex (OMJ Pharmaceuticals) |
| Drugs.com | Monografija |
| Način primene | topikalno |
| Identifikatori | |
| CAS broj | 165101-51-9  |
| ATC kod | D03AX06 (WHO), A01AD08 |
| DrugBank | DB00102 |
| ChEMBL | CHEMBL1201556 |
Reference uredi
- ^ Nagai MK, Embil JM (2002). „Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers”. Expert Opin Biol Ther. 2 (2): 211—8. PMID 11849120. doi:10.1517/14712598.2.2.211.
- ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709
. PMID 21059682. doi:10.1093/nar/gkq1126.
- ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
Literatura uredi
- Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
- Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.
Spoljašnje veze uredi
 | Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |
